Literature DB >> 25850754

Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.

Verena Sailer1, Christine Lüders, Walther Kuhn, Volker Pelzer, Glen Kristiansen.   

Abstract

As a result of breast cancer screening programs, high-grade ductal carcinoma in situ (DCIS) of the breast is diagnosed more often. Frequently, a DCIS diagnosis can only be made using immunohistochemical stains to visualize the myoepithelial layer in order to assess microinvasion. Standard markers for myoepithelial cells are CK5/6 and p63. An isoform of the latter, ∆Np63, is recognized by a recently developed antibody, p40. Here, we compare the standard myoepithelial markers CK5/6 and p63 with p40. We immunostained full sections of tissue samples of 35 high-grade DCIS and compared the staining pattern of CK5/6, p63 and p40 in tumour tissue and in normal glands. Staining patterns of myoepithelial cells for p63 and p40 were similar in terms of the percentage of stained nuclei. In all cases, p63 was strongly expressed, while this was the case for p40 in 31 (89%) and moderately in 4 (11%) cases. All but one case (97%) showed a similar percentage of stained myoepithelial cells in comparing CK5/6 and p40 staining. CK5/6 expression was heterogeneous and strong/moderate/weak in 60, 34 and 6 % respectively. Compared to surrounding normal glands, staining of myoepithelial cells for all three markers in the neoplastic lesion was attenuated. In high-grade DCIS, p40 staining is highly specific for myoepithelial cells. Its staining pattern and intensity are equal to p63, which opens up its use for daily practice. Staining with p40 is less heterogeneous than that for CK5/6.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25850754     DOI: 10.1007/s00428-015-1766-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  26 in total

1.  The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.

Authors:  G M K Tse; P-H Tan; P C W Lui; C B Gilks; C S P Poon; T K F Ma; B K B Law; W W M Lam
Journal:  J Clin Pathol       Date:  2006-05-12       Impact factor: 3.411

2.  The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast.

Authors:  Yanping Ding; Qiurong Ruan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

3.  Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.

Authors:  Fernando Nalesso Aguiar; Henrique Nogueira Mendes; Carlos E Bacchi; Filomena Marino Carvalho
Journal:  Rev Bras Ginecol Obstet       Date:  2013-03

Review 4.  Use of immunohistochemistry in the diagnosis of problematic breast lesions.

Authors:  Andrew H S Lee
Journal:  J Clin Pathol       Date:  2013-03-13       Impact factor: 3.411

Review 5.  Progression from ductal carcinoma in situ to invasive breast cancer: revisited.

Authors:  Catherine F Cowell; Britta Weigelt; Rita A Sakr; Charlotte K Y Ng; James Hicks; Tari A King; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2013-07-12       Impact factor: 6.603

6.  Intraductal carcinoma of the breast: follow-up after biopsy only.

Authors:  D L Page; W D Dupont; L W Rogers; M Landenberger
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

7.  Comparison of p40 (ΔNp63) and p63 expression in prostate tissues--which one is the superior diagnostic marker for basal cells?

Authors:  Verena Sailer; Carsten Stephan; Nicolas Wernert; Sven Perner; Klaus Jung; Manfred Dietel; Glen Kristiansen
Journal:  Histopathology       Date:  2013-05-13       Impact factor: 5.087

8.  p63 expression in normal, hyperplastic and malignant breast tissues.

Authors:  Xiaojuan Wang; Ichiro Mori; Weihua Tang; Misa Nakamura; Yasushi Nakamura; Misako Sato; Takeo Sakurai; Kennichi Kakudo
Journal:  Breast Cancer       Date:  2002       Impact factor: 4.239

Review 9.  Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression.

Authors:  Sanford H Barsky; Nina J Karlin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-07       Impact factor: 2.698

Review 10.  The benefits and harms of breast cancer screening: an independent review.

Authors: 
Journal:  Lancet       Date:  2012-10-30       Impact factor: 79.321

View more
  3 in total

1.  Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells.

Authors:  Kathryn E Yoh; Kausik Regunath; Asja Guzman; Seung-Min Lee; Neil T Pfister; Olutosin Akanni; Laura J Kaufman; Carol Prives; Ron Prywes
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-28       Impact factor: 11.205

2.  p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.

Authors:  Philip J Coates; Rudolf Nenutil; Jitka Holcakova; Marta Nekulova; Jan Podhorec; Marek Svoboda; Borivoj Vojtesek
Journal:  Virchows Arch       Date:  2018-02-27       Impact factor: 4.064

3.  Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis.

Authors:  Cecilia W Huo; Mark Waltham; Christine Khoo; Stephen B Fox; Prue Hill; Shou Chen; Grace L Chew; John T Price; Chau H Nguyen; Elizabeth D Williams; Michael Henderson; Erik W Thompson; Kara L Britt
Journal:  Breast Cancer Res       Date:  2016-10-25       Impact factor: 6.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.